The Acalabrutinib Market continues to expand as hematologists and oncologists increasingly embrace this next-generation Bruton's tyrosine kinase inhibitor for its improved selectivity and favorable safety profile in treating B-cell malignancies. With acalabrutinib demonstrating potent efficacy in chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma while minimizing...